Literature DB >> 11883280

[Serum and peritoneal fluid CA-125 concentration in women with endometriosis].

D Kraśnicki1.   

Abstract

OBJECTIVE: To evaluate the clinical utility of CA-125 measurements in peritoneal fluid (PF) as an indicator of endometriosis.
DESIGN: CA-125 levels in paired serum and peritoneal fluid were assessed by IMx CA-125 Assay (ABBOTT). PATIENTS: 107 women with and without endometriosis, undergoing laparoscopy during the luteal phase of the menstrual cycle were selected for the study.
RESULTS: CA-125 levels in peritoneal fluid were higher than those found in serum and were significantly elevated (P < 0.05) in comparison to the control group. In women with endometriosis stage I-II and stage III-IV. CA-125 levels in serum were increased only in stage III-IV.
CONCLUSIONS: The sensitivity of the peritoneal fluid CA-125 test for endometriosis is higher than the respective serum test. The measurement of CA-125 levels in PF could be useful in the detection of the early stage endometriosis, which seems to be missed by the CA-125 serum test.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11883280

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  3 in total

Review 1.  Blood biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull
Journal:  Cochrane Database Syst Rev       Date:  2016-05-01

2.  Serum levels of vascular endothelial growth factor and cancer antigen 125 are related to the prognosis of adenomyosis patients after interventional therapy.

Authors:  Yongxu Mu; Xiaoyan Hu; Junfeng He; Haiyan Liu; Lei Zhang; Heming Liu; Zhiming Hao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  CA-125 concentration in serum and peritoneal fluid in patients with endometriosis - preliminary results.

Authors:  Maria Szubert; Jacek Suzin; Tomasz Wierzbowski; Katarzyna Kowalczyk-Amico
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.